A Study to Test How Well Different Doses of BI 3706674 Are Tolerated by People With Advanced Cancer in the Stomach and Oesophagus

NCT06056024 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

47

Enrollment

INDUSTRY

Sponsor class

Conditions

Solid Tumor, KRAS Mutation

Interventions

DRUG: BI 3706674

Sponsor

Boehringer Ingelheim